KYUNG NAM PHARM.CO.,LTD. Logo

KYUNG NAM PHARM.CO.,LTD.

South Korean maker of OTC medicines, health foods, and cosmetics, known for its Lemona Vitamin C.

053950 | KO

Overview

Corporate Details

ISIN(s):
KR7053950002
LEI:
Country:
South Korea
Address:
경상남도 의령군 동동리 1539-5, 의령군
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Established in 1957, Kyung Nam Pharm Co., Ltd. is a South Korean pharmaceutical company specializing in the manufacturing and sale of over-the-counter (OTC) medicines, health functional foods, and cosmetics. The company is renowned for its flagship brand, Lemona, which was introduced in 1983 as the country's first powdered Vitamin C and has since become a leading product in the vitamin and inner-beauty markets. Its portfolio also includes well-known OTC products such as 'PM' for athlete's foot and 'Minol F Troche' for sore throats. Kyung Nam Pharm is also a prominent manufacturer of human placenta-based medicines, reinforcing its long-standing focus on consumer health and wellness.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-09-10 00:00
Share Issue/Capital Change
전환가액의조정
Korean 22.8 KB
2025-08-22 00:00
Major Shareholding Notification
주식등의대량보유상황보고서(일반)
Korean 87.5 KB
2025-08-14 00:00
Interim Report
반기보고서 (2025.06)
Korean 1.2 MB
2025-08-11 00:00
Share Issue/Capital Change
전환가액의조정
Korean 22.0 KB
2025-07-10 00:00
Share Issue/Capital Change
전환가액의조정
Korean 21.6 KB
2025-06-27 00:00
Major Shareholding Notification
주식등의대량보유상황보고서(일반)
Korean 97.1 KB
2025-06-23 00:00
Share Issue/Capital Change
전환가액의조정
Korean 14.4 KB
2025-06-10 00:00
Share Issue/Capital Change
전환가액의조정
Korean 21.1 KB
2025-05-21 00:00
Major Shareholding Notification
주식등의대량보유상황보고서(일반)
Korean 87.6 KB
2025-05-15 00:00
Quarterly Report
분기보고서 (2025.03)
Korean 1.5 MB
2025-05-12 00:00
Share Issue/Capital Change
전환가액의조정
Korean 20.7 KB
2025-04-10 00:00
Share Issue/Capital Change
전환가액의조정
Korean 20.7 KB
2025-03-20 00:00
Post-Annual General Meeting Information
정기주주총회결과
Korean 18.9 KB
2025-03-12 00:00
Audit Report / Information
사업보고서 (2024.12)
Korean 581.0 KB
2025-03-10 00:00
Share Issue/Capital Change
전환가액의조정
Korean 20.3 KB

Automate Your Workflow. Get a real-time feed of all KYUNG NAM PHARM.CO.,LTD. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for KYUNG NAM PHARM.CO.,LTD.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for KYUNG NAM PHARM.CO.,LTD. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Genmab Logo
Creates and develops antibody therapeutics for the treatment of cancer and serious diseases.
Denmark
GMAB
GENOLUTION INC. Logo
Develops molecular diagnostic and RNAi solutions for genetic testing and life sciences research.
South Korea
225220
Genome&Company Logo
Clinical-stage biopharma developing cancer therapies using microbiome, immune inhibitors, and ADCs.
South Korea
314130
Develops molecular diagnostics using DNA methylation biomarkers for early cancer detection.
South Korea
228760
Genomtec S.A. Logo
Develops a mobile platform for rapid, precise genetic diagnostics at the point-of-care.
Poland
GMT
GENOTECH CORP. Logo
A biotech firm offering gene synthesis, genome analysis, and biopharmaceutical products globally.
South Korea
066830
Genprex, Inc. Logo
A clinical-stage firm developing non-viral gene therapies for cancer and diabetes.
United States of America
GNPX
Gentian Diagnostics ASA Logo
Develops & manufactures IVD immunoassays for human & veterinary disease diagnostics.
Norway
GENT
GERON CORP Logo
Commercializes an approved, first-in-class telomerase inhibitor for blood cancers.
United States of America
GERN
GH Research PLC Logo
Clinical-stage biopharma developing mebufotenin therapies for psychiatric disorders.
United States of America
GHRS

Talk to a Data Expert

Have a question? We'll get back to you promptly.